These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

308 related articles for article (PubMed ID: 24150894)

  • 1. Sex and ESR1 genotype may influence the response to treatment with donepezil and rivastigmine in patients with Alzheimer's disease.
    Scacchi R; Gambina G; Broggio E; Corbo RM
    Int J Geriatr Psychiatry; 2014 Jun; 29(6):610-5. PubMed ID: 24150894
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cholinesterase inhibitors for Alzheimer's disease.
    Birks J
    Cochrane Database Syst Rev; 2006 Jan; 2006(1):CD005593. PubMed ID: 16437532
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of cholinesterase inhibitor utilization patterns and associated health care costs in Alzheimer's disease.
    Mucha L; Shaohung S; Cuffel B; McRae T; Mark TL; Del Valle M
    J Manag Care Pharm; 2008 Jun; 14(5):451-61. PubMed ID: 18597574
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of donepezil, galantamine and rivastigmine in 938 Italian patients with Alzheimer's disease: a prospective, observational study.
    Santoro A; Siviero P; Minicuci N; Bellavista E; Mishto M; Olivieri F; Marchegiani F; Chiamenti AM; Benussi L; Ghidoni R; Nacmias B; Bagnoli S; Ginestroni A; Scarpino O; Feraco E; Gianni W; Cruciani G; Paganelli R; Di Iorio A; Scognamiglio M; Grimaldi LM; Gabelli C; Sorbi S; Binetti G; Crepaldi G; Franceschi C
    CNS Drugs; 2010 Feb; 24(2):163-76. PubMed ID: 20088621
    [TBL] [Abstract][Full Text] [Related]  

  • 5. BCHE and CYP2D6 genetic variation in Alzheimer's disease patients treated with cholinesterase inhibitors.
    Chianella C; Gragnaniello D; Maisano Delser P; Visentini MF; Sette E; Tola MR; Barbujani G; Fuselli S
    Eur J Clin Pharmacol; 2011 Nov; 67(11):1147-57. PubMed ID: 21630031
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Variability of AChE, BChE, and ChAT genes in the late-onset form of Alzheimer's disease and relationships with response to treatment with Donepezil and Rivastigmine.
    Scacchi R; Gambina G; Moretto G; Corbo RM
    Am J Med Genet B Neuropsychiatr Genet; 2009 Jun; 150B(4):502-7. PubMed ID: 18780301
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of antipsychotic drugs in patients with Alzheimer's disease treated with rivastigmine versus donepezil: a retrospective, parallel-cohort, hypothesis-generating study.
    Scharre DW; Vekeman F; Lefebvre P; Mody-Patel N; Kahler KH; Duh MS
    Drugs Aging; 2010 Nov; 27(11):903-13. PubMed ID: 20964464
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Response to rivastigmine or donepezil in Alzheimer's patients with symptoms suggestive of concomitant Lewy body pathology.
    Touchon J; Bergman H; Bullock R; Rapatz G; Nagel J; Lane R
    Curr Med Res Opin; 2006 Jan; 22(1):49-59. PubMed ID: 16393430
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Donepezil and rivastigmine in the treatment of Alzheimer's disease: a best-evidence synthesis of the published data on their efficacy and cost-effectiveness.
    Wolfson C; Oremus M; Shukla V; Momoli F; Demers L; Perrault A; Moride Y
    Clin Ther; 2002 Jun; 24(6):862-86; discussion 837. PubMed ID: 12117079
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Functional response to cholinesterase inhibitor therapy in a naturalistic Alzheimer's disease cohort.
    Wattmo C; Wallin AK; Minthon L
    BMC Neurol; 2012 Nov; 12():134. PubMed ID: 23126532
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A longitudinal study of risk factors for community-based home help services in Alzheimer's disease: the influence of cholinesterase inhibitor therapy.
    Wattmo C; Paulsson E; Minthon L; Londos E
    Clin Interv Aging; 2013; 8():329-39. PubMed ID: 23682212
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rivastigmine and donepezil treatment in moderate to moderately-severe Alzheimer's disease over a 2-year period.
    Bullock R; Touchon J; Bergman H; Gambina G; He Y; Rapatz G; Nagel J; Lane R
    Curr Med Res Opin; 2005 Aug; 21(8):1317-27. PubMed ID: 16083542
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of age on response to rivastigmine or donepezil in patients with Alzheimer's disease.
    Bullock R; Bergman H; Touchon J; Gambina G; He Y; Nagel J; Lane R
    Curr Med Res Opin; 2006 Mar; 22(3):483-94. PubMed ID: 16574032
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of butyrylcholinesterase genotype on the response to rivastigmine or donepezil in younger patients with Alzheimer's disease.
    Blesa R; Bullock R; He Y; Bergman H; Gambina G; Meyer J; Rapatz G; Nagel J; Lane R
    Pharmacogenet Genomics; 2006 Nov; 16(11):771-4. PubMed ID: 17047484
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Switching cholinesterase inhibitor therapy in Alzheimer's disease--donepezil to rivastigmine, is it worth it?
    Bullock R; Connolly C
    Int J Geriatr Psychiatry; 2002 Mar; 17(3):288-9. PubMed ID: 11921158
    [No Abstract]   [Full Text] [Related]  

  • 16. A systematic review of the clinical effectiveness of donepezil, rivastigmine and galantamine on cognition, quality of life and adverse events in Alzheimer's disease.
    Takeda A; Loveman E; Clegg A; Kirby J; Picot J; Payne E; Green C
    Int J Geriatr Psychiatry; 2006 Jan; 21(1):17-28. PubMed ID: 16323253
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Patterns of cholinesterase-inhibitor use in the nursing home setting: a retrospective analysis.
    Dybicz SB; Keohane DJ; Erwin WG; McRae T; Shah SN
    Am J Geriatr Pharmacother; 2006 Jun; 4(2):154-60. PubMed ID: 16860262
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Which cholinesterase inhibitor is the safest for the heart in elderly patients with Alzheimer's disease?
    Isik AT; Bozoglu E; Yay A; Soysal P; Ateskan U
    Am J Alzheimers Dis Other Demen; 2012 May; 27(3):171-4. PubMed ID: 22573283
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Drug persistency patterns for patients treated with rivastigmine or donepezil in usual care settings.
    Mauskopf JA; Paramore C; Lee WC; Snyder EH
    J Manag Care Pharm; 2005 Apr; 11(3):231-51. PubMed ID: 15804207
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An open-label, comparative study of rivastigmine, donepezil and galantamine in a real-world setting.
    Aguglia E; Onor ML; Saina M; Maso E
    Curr Med Res Opin; 2004 Nov; 20(11):1747-52. PubMed ID: 15537474
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.